These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38951303)

  • 21. New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction.
    Patel S; Veltri K
    J Pharm Pract; 2017 Oct; 30(5):541-548. PubMed ID: 27194070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vericiguat in heart failure with reduced ejection fraction: hope or solid reality?
    Correale M; Pelaggi G; Catanoso MC; Miccichè S; Teresi L; Bonanno S; Bellocchi P; Poleggi C; Capasso R; Barile M; Visco V; Carluccio E; Nodari S; Ciccarelli M; Dattilo G
    Heart Fail Rev; 2024 Sep; 29(5):1135-1143. PubMed ID: 39044114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
    Armstrong PW; Pieske B; Anstrom KJ; Ezekowitz J; Hernandez AF; Butler J; Lam CSP; Ponikowski P; Voors AA; Jia G; McNulty SE; Patel MJ; Roessig L; Koglin J; O'Connor CM;
    N Engl J Med; 2020 May; 382(20):1883-1893. PubMed ID: 32222134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Pieske B; Maggioni AP; Lam CSP; Pieske-Kraigher E; Filippatos G; Butler J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Gheorghiade M
    Eur Heart J; 2017 Apr; 38(15):1119-1127. PubMed ID: 28369340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection Fraction.
    Chen PW; Trivedi A; Lee E; Dutta S; Ahamadi M
    J Cardiovasc Pharmacol; 2022 Apr; 79(4):539-548. PubMed ID: 34983909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
    Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Adams KF; Anand I; Arias-Mendoza A; Biering-Sørensen T; Böhm M; Bonderman D; Cleland JGF; Corbalan R; Crespo-Leiro MG; Dahlström U; Echeverria LE; Fang JC; Filippatos G; Fonseca C; Goncalvesova E; Goudev AR; Howlett JG; Lanfear DE; Li J; Lund M; Macdonald P; Mareev V; Momomura SI; O'Meara E; Parkhomenko A; Ponikowski P; Ramires FJA; Serpytis P; Sliwa K; Spinar J; Suter TM; Tomcsanyi J; Vandekerckhove H; Vinereanu D; Voors AA; Yilmaz MB; Zannad F; Sharpsten L; Legg JC; Varin C; Honarpour N; Abbasi SA; Malik FI; Kurtz CE;
    N Engl J Med; 2021 Jan; 384(2):105-116. PubMed ID: 33185990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
    Armstrong PW; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; She L; Vlajnic V; Carvalho F; Bamber L; Blaustein RO; Roessig L; Butler J;
    JAMA; 2020 Oct; 324(15):1512-1521. PubMed ID: 33079152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
    Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
    JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of omecamtiv mecarbil for heart failure: A systematic review and meta-analysis.
    Alqatati F; Elbahnasawy M; Bugazia S; Ragab KM; Elsnhory AB; Shehata M; Elsayed SM; Fathy MA; Nourelden AZ
    Indian Heart J; 2022; 74(3):155-162. PubMed ID: 35301008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.
    Teerlink JR; Felker GM; McMurray JJ; Solomon SD; Adams KF; Cleland JG; Ezekowitz JA; Goudev A; Macdonald P; Metra M; Mitrovic V; Ponikowski P; Serpytis P; Spinar J; Tomcsányi J; Vandekerckhove HJ; Voors AA; Monsalvo ML; Johnston J; Malik FI; Honarpour N;
    Lancet; 2016 Dec; 388(10062):2895-2903. PubMed ID: 27914656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat.
    Sepehrvand N; Islam S; Dover DC; Kaul P; McAlister FA; Armstrong PW; Ezekowitz JA
    J Card Fail; 2022 Aug; 28(8):1298-1308. PubMed ID: 35589087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac and Hemodynamic Benefits: Mode of Action of Ivabradine in Heart Failure.
    Pereira-Barretto AC
    Adv Ther; 2015 Oct; 32(10):906-19. PubMed ID: 26521191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacology of heart failure: From basic science to novel therapies.
    Lother A; Hein L
    Pharmacol Ther; 2016 Oct; 166():136-49. PubMed ID: 27456554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
    Gheorghiade M; Greene SJ; Butler J; Filippatos G; Lam CS; Maggioni AP; Ponikowski P; Shah SJ; Solomon SD; Kraigher-Krainer E; Samano ET; Müller K; Roessig L; Pieske B;
    JAMA; 2015 Dec; 314(21):2251-62. PubMed ID: 26547357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.
    Solomon SD; Claggett BL; Miao ZM; Diaz R; Felker GM; McMurray JJV; Metra M; Corbalan R; Filippatos G; Goudev AR; Mareev V; Serpytis P; Suter T; Yilmaz MB; Zannad F; Kupfer S; Heitner SB; Malik FI; Teerlink JR
    Eur Heart J; 2022 Jun; 43(23):2212-2220. PubMed ID: 35325102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential new drug treatments for congestive heart failure.
    Tran HA; Lin F; Greenberg BH
    Expert Opin Investig Drugs; 2016 Jul; 25(7):811-26. PubMed ID: 27104862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ivabradine in Management of Heart Failure: a Critical Appraisal.
    Orasanu G; Al-Kindi SG; Oliveira GH
    Curr Heart Fail Rep; 2016 Feb; 13(1):60-9. PubMed ID: 26797824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.
    Psotka MA; Teerlink JR
    Handb Exp Pharmacol; 2017; 243():465-490. PubMed ID: 28315072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trial.
    Docherty KF; McMurray JJV; Claggett BL; Miao ZM; Adams KF; Arias-Mendoza A; Cleland JGF; Diaz R; Echeverria Correa LE; Felker GM; Fonseca C; Li J; Metra M; Sliwa-Hahnle K; Solomon SD; Vandekerckhove HJ; Vinereanu D; Voors AA; Heitner SB; Kupfer S; Malik FI; Meng L; Teerlink JR
    Eur J Heart Fail; 2023 Feb; 25(2):248-259. PubMed ID: 36597719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time to benefit of heart rate reduction with ivabradine in patients with heart failure and reduced ejection fraction.
    Böhm M; Abdin A; Slawik J; Mahfoud F; Borer J; Ford I; Swedberg K; Tavazzi L; Batailler C; Komajda M
    Eur J Heart Fail; 2023 Aug; 25(8):1429-1435. PubMed ID: 37092340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.